Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

BET Protein Antagonist-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Bernardo H Lara, Christine Birdwell, Michael R Green, PhD, Joseph D. Khoury, MD, Kapil N. Bhalla, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-138637

Published: 2020

Journal Articles

Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-136756

Published: 2020

Journal Articles

Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-134778

Published: 2020

Journal Articles

Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Blood (2020) 136 (Supplement 1): 29–31.

https://doi.org/10.1182/blood-2020-137335

Published: 2020

Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 125.

https://doi.org/10.1182/blood-2019-129422

Published: 2019

Journal Articles

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Vrajesh Karkhanis, PhD, Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Abhishek Maiti, MBBS, Bernardo H Lara, James V Maher, Isean Bhalla, Nancy Shao, Michael R Green, PhD, Joseph D. Khoury, MD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 3961.

https://doi.org/10.1182/blood-2019-132041

Published: 2019

Journal Articles

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Sairah Ahmed, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael Eric Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Ken H. Young, Timothy J. McDonnell, MD PhD, Hubert Chuang, Michael R Green, PhD, Sattva S Neelapu, MD, Eric Davis, MD

Blood (2019) 134 (Supplement_1): 1581.

https://doi.org/10.1182/blood-2019-128475

Published: 2019

Journal Articles

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Paolo Strati, MD, Ralph J. Johnson, PhD, Sheryl G Forbes, Loretta J. Nastoupil, MD MSc, Felipe Samaniego, MD, Eric Davis, MD, Michael R Green, PhD, Luis Fayad, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Michael L. Wang, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 1533.

https://doi.org/10.1182/blood-2019-129311

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 447.

https://doi.org/10.1182/blood-2018-99-113721

Published: 2018

Journal Articles

A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Matthew A. Lunning, DO, Philip Bierman, MD, R. Gregory Bociek, MD, James O. Armitage, MD, Peggy Heires, R.N., Maribeth Hohenstein, R.N, Susan Blumel, RN, Jonathan Tefft, B.A., Elizabeth R. Lyden, MS, Michael R Green, PhD, Julie M. Vose, MD MBA

Blood (2018) 132 (Supplement 1): 5390.

https://doi.org/10.1182/blood-2018-99-119765

Published: 2018

Journal Articles

Repression of the Orphan Nuclear Receptor Esrrb Results in Glucocorticoid Resistance in ALL

Kayleigh Gallagher, BS, Justine E. Roderick, PhD, Jun Yu, Julie Zhu, Michael R Green, PhD, Michelle Kelliher, PhD

Blood (2017) 130 (Supplement 1): 1259.

https://doi.org/10.1182/blood.V130.Suppl_1.1259.1259

Published: 2017

Journal Articles

Reproducibility of m7-FLIPI Risk Scores in Follicular Lymphoma Using Tumor Biopsies and Blood Specimens

Joanne Soo, BS, Florian Scherer, MD, David M. Kurtz, MD, Joseph G Schroers-Martin, MD, Michael Jin, Alexander Craig, MPhil, Henning Stehr, PhD, Chih Long Liu, PhD, Michael R Green, PhD, Oliver Weigert, MD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MDPhD

Blood (2017) 130 (Supplement 1): 1466.

https://doi.org/10.1182/blood.V130.Suppl_1.1466.1466

Published: 2017

Journal Articles

Vitamin K3 (menadione) Induces Cytotoxicity in Chronic Myeloid Leukemia Stem Cells By Upregulating DYRK2 through the Inhibition of SIAH2 Ubiquitin Ligase

Chun Shik Park, PhD, Ye Shen, PhD, Andrew H Lewis, BS, Koramit Suppipat, MD, Monica Puppi, Julie Tomolonis, Taylor J Chen, Paul Pang, Toni-Ann Mistretta, Leyuan Ma, Michael R Green, PhD, Rachel E. Rau, MD, H. Daniel Lacorazza, PhD

Blood (2017) 130 (Supplement 1): 4171.

https://doi.org/10.1182/blood.V130.Suppl_1.4171.4171

Published: 2017

Journal Articles

DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma

Blood (2016) 128 (22): 2686.

https://doi.org/10.1182/blood.V128.22.2686.2686

Published: 2016

Journal Articles

Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target

Blood (2016) 128 (22): 4095.

https://doi.org/10.1182/blood.V128.22.4095.4095

Published: 2016

Journal Articles

CREBBP Loss Cooperates with BCL2 Over-Expression to Promote Lymphoma in Mice

Blood (2016) 128 (22): 458.

https://doi.org/10.1182/blood.V128.22.458.458

Published: 2016

Journal Articles

Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens

Blood (2016) 128 (22): 915.

https://doi.org/10.1182/blood.V128.22.915.915

Published: 2016

Journal Articles

The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL)

Colm Keane, MB BCh BAO MSc MBA MRCPI FRCPath FRCPA PhD, Kimberly Jones, PhD, Clare Gould, MBBS, David Hamm, Peter Wood, MD FRACP, FRCPA, MBBS, Simone Birch, FRCPA PhD, Pauline Crooks, BSc, Michael R Green, PhD, Dipti Taulaulikar, MBBS, PhD FRACP, FRCPA,, Sanjiv Jain, FRCPA, Josh Tobin, MBBS, Maher K Gandhi, PhDFRACP FRCPath FRCP

Blood (2015) 126 (23): 3893.

https://doi.org/10.1182/blood.V126.23.3893.3893

Published: 2015

Journal Articles

Loss of Heterozygosity (LOH) of PTPRJ in Non-Hodgkin`s Lymphoma (NHL)

Carlos A Aya-Bonilla, MSc, PhD student, Michael R Green, PhD, Emily Camilleri, Hons, PhD Student, Paula Marlton, MBBS, Rod Lea, PhD, Maher Gandhi, PhD, FRACP, FRCPath, FRCP, Lyn R Griffiths, Hons, PhD

Blood (2011) 118 (21): 5231.

https://doi.org/10.1182/blood.V118.21.5231.5231

Published: 2011

Journal Articles

Mir-15a/16-1 Cluster Is Frequently Deleted In Primary Hodgkin Lymphoma and Modulates Multiple Survival Pathways Including AP-1

Bjoern Chapuy, MD, PhD, Michael R Green, PhD, Jun Lu, PhD, Stefano Monti, PhD, Yansheng Hao, MD, PhD, Kelly T Yeda, Scott J Rodig, Treeve Currie, Kunihiko Takeyama, MD, PhD, Todd R Golub, MD, PhD, Jeffery Kutok, MD, PhD, Margaret A. Shipp, MD

Blood (2010) 116 (21): 746.

https://doi.org/10.1182/blood.V116.21.746.746

Published: 2010

NARROW

BET Protein Antagonist-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies

Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Repression of the Orphan Nuclear Receptor Esrrb Results in Glucocorticoid Resistance in ALL

Reproducibility of m7-FLIPI Risk Scores in Follicular Lymphoma Using Tumor Biopsies and Blood Specimens

Vitamin K3 (menadione) Induces Cytotoxicity in Chronic Myeloid Leukemia Stem Cells By Upregulating DYRK2 through the Inhibition of SIAH2 Ubiquitin Ligase

DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma

Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target

CREBBP Loss Cooperates with BCL2 Over-Expression to Promote Lymphoma in Mice

Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens

The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL)

Loss of Heterozygosity (LOH) of PTPRJ in Non-Hodgkin`s Lymphoma (NHL)

Mir-15a/16-1 Cluster Is Frequently Deleted In Primary Hodgkin Lymphoma and Modulates Multiple Survival Pathways Including AP-1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only